Business Wire

Adva Network Security Layer 2 encryption technology achieves German BSI approval

Share

Adva Network Security today announced that its flagship 10Gbit/s edge solution with ConnectGuard Ethernet encryption has been approved for the transmission of classified data by the German Federal Office for Information Security (BSI). With BSI clearance to transport VS-NfD and NATO RESTRICTED (NR) information, the FSP 150-XG118Pro (CSH) enables customers to deploy a secure network access device guaranteed to meet stringent regulatory requirements. With comprehensive demarcation capabilities and an optional server blade, the device offers several additional advantages, such as precise synchronization and NFV hosting. Its approval by the BSI will be a major boost for customers with high security standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005865/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BSI approval for Adva Network Security’s 10G Ethernet device will prove key for data protection at the network edge. (Photo: Business Wire)

“We work with public authorities, critical infrastructure operators and enterprises whose networks are particularly threatened by cyberattacks as they often contain the most sensitive and mission-critical data. Today’s announcement will be big news for them. Now it’s possible to securely harness a 10Gbit/s edge solution with a unique set of capabilities such as next-generation timing delivery, network virtualization and comprehensive service assurance,” said Michael Roth, GM of Adva Network Security. “We were the first in the industry to attain BSI clearance for our Layer 1 technology. Now it’s the turn of our Layer 2 solution. As a qualification, BSI approval is one of the most challenging in the industry. Achieving it not only highlights the power of the protection offered by our device, but also our commitment to security in all our business processes.”

The FSP 150-XG118Pro (CSH) is a compact, power-efficient solution for network access that combines 10Gbit/s Carrier Ethernet, IP service demarcation, and aggregation with a rich set of programmability and synchronization features. It offers robust network protection with dynamic key exchange and hardware tamper protection for the most sensitive data, and is also ready to support quantum-safe key exchange. The approval of the FSP 150-XG118Pro (CSH) by the BSI follows certification for the ADVA FSP 3000 Layer 1 encryption solution, which is already playing a key role in the transport of EU- and NATO-classified data. Customers can now have complete peace of mind that their data at both Layers 1 and 2 is secured to the most rigorous standards and compliance requirements.

“Public authorities and critical infrastructure use wide area networks and are looking to apply end-to-end encryption to standard MEF services that meet the strictest industry standards. Now our FSP 150-XG118Pro (CSH) offers a solution that ensures BSI-approved security for metro networks along with the key capabilities needed to deliver tomorrow’s services,” commented Uli Schlegel, senior director of product line management at Adva Network Security. “Our FSP 150-XG118Pro (CSH) meets tight constraints for latency, power and size. It includes a rich set of operational features and supports a pluggable server module for hosting virtualized network functions. With BSI approval, it’s the ultimate choice for rapid innovation and security at the network edge.”

Further information on the FSP 150-XG118Pro (CSH) is available in this video: https://youtu.be/6w7Z3CLBRFE.

About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuardTM security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom